Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
暂无分享,去创建一个
G. Feldmann | M. Essler | M. Schreckenberger | P. Brossart | M. Miederer | Matthias M. Weber | A. Yordanova | H. Ahmadzadehfar | F. Gaertner | C. Fottner | H. Ahrens | M. Weber
[1] W. Fu,et al. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms , 2018, Medicine.
[2] C. Fottner,et al. Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts , 2018, Wiener klinisches Magazin.
[3] R. Fimmers,et al. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy , 2018, Clinical Cancer Research.
[4] S. Basu,et al. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE , 2017, Clinical nuclear medicine.
[5] C. Strassburg,et al. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[6] G. Kristiansen,et al. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours , 2017, Hormone and Metabolic Research.
[7] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[8] B. Krause,et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. , 2016, European journal of cancer.
[9] E. Krenning,et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.
[10] E. Krenning,et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.
[11] M. Cuggia,et al. High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation , 2014, The Journal of Nuclear Medicine.
[12] T. Höller,et al. Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18F-FDG PET: Feasibility of a Metabolic Grading System , 2014, The Journal of Nuclear Medicine.
[13] R. Hicks,et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT) , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[14] M. de Jong,et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments , 2014, Clinical and Translational Imaging.
[15] Dorte Nielsen,et al. Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab , 2013, The Journal of Nuclear Medicine.
[16] J. Chabot,et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience , 2013, Cancer Chemotherapy and Pharmacology.
[17] W. Willinek,et al. 90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy , 2012, The Journal of Nuclear Medicine.
[18] J. Turner,et al. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. , 2012, Cancer biotherapy & radiopharmaceuticals.
[19] K. Öberg,et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] M. Anlauf. Neuroendocrine Neoplasms of the Gastroenteropancreatic System: Pathology and Classification , 2011, Hormone and Metabolic Research.
[21] Rakesh Kumar,et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids , 2011, Cancer imaging : the official publication of the International Cancer Imaging Society.
[22] Matthias Briel,et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[24] J. Turner,et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[25] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[26] M. Papotti,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification , 2008, Neuroendocrinology.
[27] A. Faggiano,et al. The biological characterization of neuroendocrine tumors: The role of neuroendocrine markers , 2008, Journal of endocrinological investigation.
[28] E. Krenning,et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[29] G. Klöppel,et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors , 2007, Virchows Archiv.
[30] S. Lamberts,et al. The pathophysiological consequences of somatostatin receptor internalization and resistance. , 2003, Endocrine reviews.
[31] Eva Segelov,et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors , 2017, Pancreas.